Insurance Coverage: Many major insurance plans no longer cover Onglyza starting in 2016. Learn More
Savings Alert: We've added new, lower prices at most pharmacies for this prescription. Learn More
Onglyza (saxagliptin) is used to control blood sugar and treat type 2 diabetes. Onglyza is less popular than comparable gliptins. There are currently no generic alternatives to Onglyza.
GoodRx has partnered with Inside Rx and AstraZeneca to reduce the price for this prescription by up to 25%. Check our savings tips for co-pay cards, assistance programs, and other ways to reduce your cost. Onglyza is covered by some Medicare and insurance plans.
Get the latest updates on this drug from the GoodRx medical team
The GoodRx Pharmacist - March 10, 2017
According to The American Diabetes Association, as of 2012, type 2 diabetes affected 29.1 million Americans, 9.3% of the population. Every year another 1.4 million Americans are diagnosed with type 2 diabetes, which can lead to live-threatening complications like high-blood pressure, kidney disease, high cholesterol, or loss of vision.
Recently, the FDA approved Qtern (dapagliflozin and saxagliptin), a new combination prescription medication for adults with type 2 diabetes. See More
Dr. Sharon Orrange - October 06, 2015
More than 29 million Americans have diabetes. That’s more than 10% of the US—and that number continues to rise. More than 1.7 million adults were diagnosed with diabetes in 2012 alone.
Fortunately, several new medications for diabetes have recently been approved—Toujeo (a new insulin product), Synjardy (a new combination of empagliflozin/metformin) and others. These new drugs provide several benefits such as fewer side effects or foolproof self-dosing with an insulin pen. See More
The GoodRx Pharmacist - September 04, 2015
On August 28, 2015, the FDA issued a safety warning for a newer type of type 2 diabetes medication known as DPP-4 inhibitors or gliptins.
There have been reports that these medications can cause severe and possibly disabling joint pain.
Which medications contain gliptins (DPP-4 inhibitors)?
Why was a FDA safety warning issued for gliptin medications?
The FDA issued the warning due to continued reports of severe joint pain associated with the use of gliptin medications. See More
Elizabeth Davis - August 12, 2015
It’s that time again—the new lists of covered and excluded drugs on next year’s insurance plans are out, and it doesn’t look great. For many Americans with health insurance, more than 50 popular brand-name and generic drugs may no longer be covered starting in January 2016.
Express Scripts and Caremark, companies that handles pharmacy benefits for more than 200 million Americans, are removing about 20 – 30 drugs each from their national preferred formularies at the end of 2015. See More
Dr. Sharon Orrange - January 02, 2014
2013 was a year for many new treatments for type II diabetes. For healthcare workers and patients it’s hard to keep up with the newer medications for the treatment of adult onset diabetes, and treating diabetes is an art and not a “one-size fits all” algorithm. For our folks struggling with type II diabetes the outlook just got brighter because of a class of drugs known as incretin based drugs. Here is the down-low on these medications. See More
Elizabeth Davis - October 29, 2013
For many Americans with health insurance, more than 50 popular brand-name drugs may no longer be covered starting in January 2014. Express Scripts and Caremark, companies that handles pharmacy benefits for more than 200 million Americans, are removing almost 50 brands from their formularies at the end of 2013. More information is below.
What are Express Scripts and Caremark?
Express Scripts and Caremark are companies that administer prescription drug benefits for many health insurance companies and Tricare. See More